Indivior Pharmaceuticals, Inc. (INDV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 500M 1B 1.5B FY21: 791M FY22: 901M FY23: 1.1B FY24: 1.2B FY25: 1.2B FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 350M 700M 1.1B FY21: 664M FY22: 749M FY23: 919M FY24: 957M FY25: 994M FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-180M -90M 0 90M 180M 270M FY21: 213M FY22: -81M FY23: -152M FY24: 38M FY25: 262M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-160M -80M 0 80M 160M 240M FY21: 205M FY22: -44M FY23: -126M FY24: 7M FY25: 210M FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 90M 180M 270M FY21: 127M FY22: 151M FY23: 174M FY24: 231M FY25: 246M FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-450M -300M -150M 0 150M 300M 450M FY21: 353M FY22: -4M FY23: -300M FY24: 36M FY25: -27M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-450M -300M -150M 0 150M 300M 450M FY21: 349M FY22: -9M FY23: -308M FY24: 7M FY25: -93M FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 60M 120M 180M FY21: 151.9M FY22: 139M FY23: 137M FY24: 133M FY25: 128M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.00 0.00 1.00 2.00 3.00 Q4 '24: 0.05 Q1 '25: -0.02 Q2 '25: 0.84 Q3 '25: 1.01 Q4 '25: 1.64 Q1 '26: 1.95 Q2 '26: 2.79 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.